AstraZeneca and Accent Therapeutics have entered a deal to develop and commercialize cancer treatments using RNA-modifying proteins. The deal states that Accent will be eligible for an upfront payment of $55 million and option fees, milestones and tiered royalties on net sales while being responsible for research and development activities for an unspecified preclinical program, while AstraZeneca will handle subsequent development and commercialization after regulatory approvals.
AstraZeneca, Accent partner to develop RNA-modifying proteins
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.